Insider · CIK 0001977239
Wang Chiu Wong
Files at FNVTF (Finnovate Acquisition Corp.). First filing -, latest -.
In brief
Wang Chiu Wong files SEC Form 4 as CFO and director at FNVTF (Finnovate Acquisition Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Wang Chiu Wong has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | FNVTF Finnovate Acquisition Corp. | JOther Class A Ordinary Share, par value $0.0001 per share | +15,000 | $0.00 | $0 | 15,000 | Jan 8, 2025 |
| Jan 3, 2025 | FNVTF Finnovate Acquisition Corp. | JOther Class A Ordinary Share, par value $0.0001 per shareindirect: See footnote | +211,153 | $0.00 | $0 | 211,153 | Jan 8, 2025 |
| Jan 3, 2025 | FNVTF Finnovate Acquisition Corp. | JOther Class B Ordinary Share, par value $0.0001 per sharederivativeindirect: See footnote | +1 | - | - | 1 | Jan 8, 2025 |
Questions about Wang Chiu Wong
Answered from the filings on this page, as of the latest one.
Is Wang Chiu Wong buying or selling?
Wang Chiu Wong has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Wang Chiu Wong's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Wang Chiu Wong has 0.
Where does Wang Chiu Wong file Form 4?
Wang Chiu Wong has filed Form 4 at FNVTF (Finnovate Acquisition Corp.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.